Astellas to buy GPCR specialist Ogeda for €500M upfront by Nick Paul Taylor Monday, April 3, 2017 Astellas has struck a deal to buy Ogeda for €500 million upfront to gain a potential nonhormonal treatment for menopausal hot flashes.
